{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T01:40:58Z","timestamp":1793670058417,"version":"4.5.1"},"reference-count":512,"publisher":"Harborside Press, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country\u2019s fifth most common cause of cancer mortality in women. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating in the ovary, fallopian tube, or peritoneum, as these are all managed in a similar manner. Most of the recommendations are based on data from patients with the most common subtypes\u2500high-grade serous and grade 2\/3 endometrioid. The NCCN Guidelines also include recommendations specifically for patients with less common ovarian cancers, which in the guidelines include the following: carcinosarcoma, clear cell carcinoma, mucinous carcinoma, low-grade serous, grade 1 endometrioid, borderline epithelial, malignant sex cord-stromal, and malignant germ cell tumors. This manuscript focuses on certain aspects of primary treatment, including primary surgery, adjuvant therapy, and maintenance therapy options (including PARP inhibitors) after completion of first-line chemotherapy.<\/jats:p>","DOI":"10.6004\/jnccn.2021.0007","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T19:30:02Z","timestamp":1612812602000},"page":"191-226","source":"Crossref","is-referenced-by-count":643,"title":["Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology"],"prefix":"10.6004","volume":"19","author":[{"given":"Deborah K.","family":"Armstrong","sequence":"first","affiliation":[{"name":"1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Alvarez","sequence":"additional","affiliation":[{"name":"2Vanderbilt-Ingram Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie N.","family":"Bakkum-Gamez","sequence":"additional","affiliation":[{"name":"3Mayo Clinic Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Barroilhet","sequence":"additional","affiliation":[{"name":"4University of Wisconsin Carbone Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kian","family":"Behbakht","sequence":"additional","affiliation":[{"name":"5University of Colorado Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Berchuck","sequence":"additional","affiliation":[{"name":"6Duke Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-may","family":"Chen","sequence":"additional","affiliation":[{"name":"7UCSF Helen Diller Family Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Cristea","sequence":"additional","affiliation":[{"name":"8City of Hope National Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"DeRosa","sequence":"additional","affiliation":[{"name":"9Patient Advocate;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Eisenhauer","sequence":"additional","affiliation":[{"name":"10Massachusetts General Hospital Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[{"name":"11The University of Texas MD Anderson Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J.","family":"Gray","sequence":"additional","affiliation":[{"name":"12Fred Hutchinson Cancer Research Center\/Seattle Cancer Care Alliance;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Grisham","sequence":"additional","affiliation":[{"name":"13Memorial Sloan Kettering Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardeshir","family":"Hakam","sequence":"additional","affiliation":[{"name":"14Moffitt Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Jain","sequence":"additional","affiliation":[{"name":"15Fox Chase Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Karam","sequence":"additional","affiliation":[{"name":"16Stanford Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried E.","family":"Konecny","sequence":"additional","affiliation":[{"name":"17UCLA Jonsson Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Leath","sequence":"additional","affiliation":[{"name":"18O'Neal Comprehensive Cancer Center at UAB;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Liu","sequence":"additional","affiliation":[{"name":"19Dana-Farber\/Brigham and Women\u2019s Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haider","family":"Mahdi","sequence":"additional","affiliation":[{"name":"20Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lainie","family":"Martin","sequence":"additional","affiliation":[{"name":"21Abramson Cancer Center at the University of Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Matei","sequence":"additional","affiliation":[{"name":"22Robert H. Lurie Comprehensive Cancer Center of Northwestern University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McHale","sequence":"additional","affiliation":[{"name":"23UC San Diego Moores Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"McLean","sequence":"additional","affiliation":[{"name":"24University of Michigan Rogel Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Miller","sequence":"additional","affiliation":[{"name":"25UT Southwestern Simmons Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O\u2019Malley","sequence":"additional","affiliation":[{"name":"26The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Percac-Lima","sequence":"additional","affiliation":[{"name":"10Massachusetts General Hospital Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ratner","sequence":"additional","affiliation":[{"name":"27Yale Cancer Center\/Smilow Cancer Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Remmenga","sequence":"additional","affiliation":[{"name":"28Fred & Pamela Buffett Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Vargas","sequence":"additional","affiliation":[{"name":"20Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa L.","family":"Werner","sequence":"additional","affiliation":[{"name":"29Huntsman Cancer Institute at the University of Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emese","family":"Zsiros","sequence":"additional","affiliation":[{"name":"30Roswell Park Comprehensive Cancer Center; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Burns","sequence":"additional","affiliation":[{"name":"31National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita M.","family":"Engh","sequence":"additional","affiliation":[{"name":"31National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref551","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3747\/co.19.980","article-title":"Management of a suspicious adnexal mass: a clinical practice guideline","volume":"19","author":"Dodge","year":"2012","journal-title":"Curr Oncol"},{"key":"ref2681","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/s13058-014-0475-x","article-title":"Association of BRCA1\/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes","volume":"16","author":"Timms","year":"2014","journal-title":"Breast Cancer Res"},{"key":"ref3361","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ygyno.2017.06.019","article-title":"Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer","volume":"146","author":"van de Vrie","year":"2017","journal-title":"Gynecol Oncol"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO clinical practice guideline update","volume":"36","author":"Oktay","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref3811","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1200\/JCO.2009.24.8617","article-title":"Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection","volume":"28","author":"Satoh","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref5191","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ygyno.2011.05.022","article-title":"Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer","volume":"122","author":"Landrum","year":"2011","journal-title":"Gynecol Oncol"},{"key":"ref3681","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.ejso.2018.03.001","article-title":"Laparoscopic surgery in the treatment of stage I adult granulosa cells tumors of the ovary: Results from the MITO-9 study","volume":"44","author":"Bergamini","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"ref2221","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1097\/AOG.0b013e3182922a17","article-title":"Adherence to treatment guidelines for ovarian cancer as a measure of quality care","volume":"121","author":"Bristow","year":"2013","journal-title":"Obstet Gynecol"},{"key":"ref4401","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"ref2751","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1097\/AOG.0b013e3182922a17","article-title":"Adherence to treatment guidelines for ovarian cancer as a measure of quality care","volume":"121","author":"Bristow","year":"2013","journal-title":"Obstet Gynecol"},{"key":"ref4211","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJMoa1808424","article-title":"A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms","volume":"380","author":"Harter","year":"2019","journal-title":"N Engl J Med"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1245\/s10434-008-9893-2","article-title":"Comparison of laparoscopy and laparotomy in surgical staging of early-stage ovarian and fallopian tubal cancer","volume":"15","author":"Park","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"ref4831","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1200\/JCO.2015.66.2346","article-title":"Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group Clinical Trials","volume":"34","author":"Hershman","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ygyno.2016.10.017","article-title":"Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study","volume":"143","author":"Gueli Alletti","year":"2016","journal-title":"Gynecol Oncol"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/gyno.2002.6805","article-title":"Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy","volume":"87","author":"Schilder","year":"2002","journal-title":"Gynecol Oncol"},{"key":"ref3171","doi-asserted-by":"crossref","first-page":"341","DOI":"10.23736\/S0026-4806.19.06132-9","article-title":"Laparoscopy vs. laparotomy for advanced ovarian cancer: a systematic review of the literature","volume":"110","author":"Gueli Alletti","year":"2019","journal-title":"Minerva Med"},{"key":"ref3511","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.rbmo.2018.03.018","article-title":"Survival of selected patients with ovarian cancer treated with fertility-sparing surgery","volume":"37","author":"Hedb\u00e4ck","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"ref4741","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/gyno.1997.4690","article-title":"Randomized study comparing carboplatin\/cyclophosphamide and cisplatin\/cyclophosphamide as first-line treatment in patients with stage III\/IV epithelial ovarian cancer and small volume disease","volume":"66","author":"Meerpohl","year":"1997","journal-title":"Gynecol Oncol"},{"key":"ref3881","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jpedsurg.2003.11.027","article-title":"Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study","volume":"39","author":"Billmire","year":"2004","journal-title":"J Pediatr Surg"},{"key":"ref1871","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/annonc\/mdi223","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study","volume":"16","author":"Aravantinos","year":"2005","journal-title":"Ann Oncol"},{"key":"ref2831","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ygyno.2005.07.008","article-title":"Who should operate on patients with ovarian cancer? An evidence-based review","volume":"99","author":"Giede","year":"2005","journal-title":"Gynecol Oncol"},{"key":"ref1391","first-page":"3020","article-title":"[Prognostic significance of systematic retroperitoneal lymphadenectomy in patients with epithelial ovarian cancer: a Meta-analysis]","volume":"96","author":"Gu","year":"2016","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref2501","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2214\/AJR.09.4110","article-title":"Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know","volume":"195","author":"Nishino","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"ref1761","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N Engl J Med"},{"key":"ref1971","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref2861","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2014.10.023","article-title":"Ovarian cancer in the United States: contemporary patterns of care associated with improved survival","volume":"136","author":"Cliby","year":"2015","journal-title":"Gynecol Oncol"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0029-7844(96)00021-X","article-title":"Laparotomy to complete staging of presumed early ovarian cancer","volume":"87","author":"Stier","year":"1996","journal-title":"Obstet Gynecol"},{"key":"ref1901","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref3801","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1002\/cncr.24461","article-title":"Fertility preservation in young women with epithelial ovarian cancer","volume":"115","author":"Wright","year":"2009","journal-title":"Cancer"},{"key":"ref4661","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/jnci\/djq362","article-title":"Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel","volume":"102","author":"Hoskins","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"ref931","first-page":"1001","article-title":"A Long-term follow-up study of 91 cases with ovarian granulosa cell tumors","volume":"34","author":"Shim","year":"2014","journal-title":"Anticancer Res"},{"key":"ref1291","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ygyno.2007.10.022","article-title":"The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer","volume":"108","author":"Eisenhauer","year":"2008","journal-title":"Gynecol Oncol"},{"key":"ref1951","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1093\/annonc\/mds060","article-title":"First-line treatment of advanced ovarian cancer with paclitaxel\/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG","volume":"23","author":"Lindemann","year":"2012","journal-title":"Ann Oncol"},{"key":"ref3841","first-page":"949","article-title":"Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma","volume":"80","author":"Soper","year":"1992","journal-title":"Obstet Gynecol"},{"key":"ref1501","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1200\/JCO.2009.25.3617","article-title":"Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials","volume":"28","author":"du Bois","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4293\/108680810X12785289143990","article-title":"The safety and efficacy of laparoscopic surgical staging and debulking of apparent advanced stage ovarian, fallopian tube, and primary peritoneal cancers","volume":"14","author":"Nezhat","year":"2010","journal-title":"JSLS"},{"key":"ref4901","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"ref4181","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1525-1438.1997.00418.x","article-title":"Systematic pelvic and para-aortic lymphadenectomy in advanced ovarian cancer patients with no residual intraperitoneal disease","volume":"7","author":"Scarabelli","year":"1997","journal-title":"Int J Gynecol Cancer"},{"key":"ref2691","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40364-015-0033-4","article-title":"Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs","volume":"3","author":"Marquard","year":"2015","journal-title":"Biomark Res"},{"key":"ref3011","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4293\/JSLS.2014.00232","article-title":"Laparoscopy-assisted supracervical hysterectomy for ovarian cancer: cervical recurrence","volume":"18","author":"Fanning","year":"2014","journal-title":"JSLS"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/bjc.2013.241","article-title":"Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary","volume":"109","author":"Mangili","year":"2013","journal-title":"Br J Cancer"},{"key":"ref3311","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ygyno.2013.08.005","article-title":"Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience","volume":"131","author":"Fagotti","year":"2013","journal-title":"Gynecol Oncol"},{"key":"ref2701","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jmig.2016.09.018","article-title":"Minimally invasive surgical staging for ovarian carcinoma: a propensity-matched comparison with traditional open surgery","volume":"24","author":"Ditto","year":"2017","journal-title":"J Minim Invasive Gynecol"},{"key":"ref4291","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"ref2371","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41416-019-0543-1","article-title":"Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study","volume":"121","author":"Shi","year":"2019","journal-title":"Br J Cancer"},{"key":"ref4351","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jnci\/95.2.113","article-title":"Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial","volume":"95","author":"Trimbos","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00404-018-4709-5","article-title":"Report of the survey on current opinions and practice of German Society for Gynecologic Endoscopy (AGE) members regarding the laparoscopic treatment of ovarian malignancies","volume":"297","author":"Radosa","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"ref3211","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1097\/IGC.0000000000000214","article-title":"Laparoscopic and open abdominal staging for early-stage ovarian cancer: our experience, systematic review, and meta-analysis of comparative studies","volume":"24","author":"Bogani","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jamcollsurg.2015.01.056","article-title":"Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival","volume":"220","author":"Bristow","year":"2015","journal-title":"J Am Coll Surg"},{"key":"ref4221","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1200\/JCO.2009.25.3617","article-title":"Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials","volume":"28","author":"du Bois","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref4881","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/0090-8258(92)90305-3","article-title":"Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma","volume":"45","author":"Hakes","year":"1992","journal-title":"Gynecol Oncol"},{"key":"ref3781","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/gyno.2002.6805","article-title":"Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy","volume":"87","author":"Schilder","year":"2002","journal-title":"Gynecol Oncol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the management of ovarian cancer: ASCO guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref3401","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"ref4701","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.1992.10.5.706","article-title":"Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer","volume":"10","author":"Alberts","year":"1992","journal-title":"J Clin Oncol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.1525-1438.2008.01190.x","article-title":"Laparoscopic and laparotomic staging in stage I epithelial ovarian cancer: a comparison of feasibility and safety","volume":"18","author":"Park","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"ref1821","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"ref3611","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ygyno.2006.08.032","article-title":"Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women","volume":"104","author":"Zhang","year":"2007","journal-title":"Gynecol Oncol"},{"key":"ref2841","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/jnci\/djj019","article-title":"Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients","volume":"98","author":"Earle","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"ref2541","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"ref5161","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"ref4061","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3949\/ccjm.75.Suppl_4.S17","article-title":"Update on nonhormonal approaches to menopausal management","volume":"75","author":"Jenkins","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"ref2311","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1470-2045(12)70567-3","article-title":"Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial","volume":"14","author":"Stark","year":"2013","journal-title":"Lancet Oncol"},{"key":"ref5291","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/OTT.S30238","article-title":"Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options","volume":"6","author":"Elit","year":"2013","journal-title":"OncoTargets Ther"},{"key":"ref2041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"ref2891","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1074-3804(05)60481-1","article-title":"Laparoscopic surgery for complex ovarian masses","volume":"7","author":"Ulrich","year":"2000","journal-title":"J Am Assoc Gynecol Laparosc"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.ejso.2018.03.001","article-title":"Laparoscopic surgery in the treatment of stage I adult granulosa cells tumors of the ovary: Results from the MITO-9 study","volume":"44","author":"Bergamini","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"ref1891","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djj296","article-title":"Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO","volume":"98","author":"Pfisterer","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"ref5121","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref3191","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jmig.2019.06.017","article-title":"Mortality rates in laparoscopic and robotic gynecologic oncology surgery: a systemic review and meta-analysis","volume":"26","author":"Behbehani","year":"2019","journal-title":"J Minim Invasive Gynecol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann Oncol"},{"key":"ref4241","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/jjco\/hyw068","article-title":"The effect of lymphadenectomy on survival and recurrence in patients with ovarian cancer: a systematic review and meta-analysis","volume":"46","author":"Zhou","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2020.01.033","article-title":"Trends in the surgical management of malignant ovarian germcell tumors","volume":"157","author":"Nasioudis","year":"2020","journal-title":"Gynecol Oncol"},{"key":"ref3481","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/ijgc-2020-001716","article-title":"Fertility sparing surgery for patients with FIGO stage I clear cell ovarian carcinoma: a database analysis and systematic review of the literature","volume":"30","author":"Nasioudis","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"ref3671","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1089\/jayao.2016.0086","article-title":"Fertility-sparing surgery should be the standard treatment in patients with malignant ovarian germ cell tumors","volume":"6","author":"Turkmen","year":"2017","journal-title":"J Adolesc Young Adult Oncol"},{"key":"ref5221","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2214\/AJR.09.4110","article-title":"Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know","volume":"195","author":"Nishino","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ygyno.2006.06.028","article-title":"The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer","volume":"103","author":"Eisenhauer","year":"2006","journal-title":"Gynecol Oncol"},{"key":"ref1191","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/ijgc-2019-001116","article-title":"Role of staging surgery and adjuvant chemotherapy in adult patients with apparent stage I pure immature ovarian teratoma after fertility-sparing surgery","volume":"30","author":"Wang","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"ref3051","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ygyno.2016.10.017","article-title":"Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study","volume":"143","author":"Gueli Alletti","year":"2016","journal-title":"Gynecol Oncol"},{"key":"ref4071","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1013::AID-CNCR17>3.0.CO;2-1","article-title":"Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial","volume":"86","author":"Guidozzi","year":"1999","journal-title":"Cancer"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"ref3391","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","article-title":"Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome","volume":"59","author":"Fagotti","year":"2016","journal-title":"Eur J Cancer"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000381462","article-title":"Oncologic concerns regarding laparoscopic cytoreductive surgery in patients with advanced ovarian cancer submitted to neoadjuvant chemotherapy","volume":"89","author":"Favero","year":"2015","journal-title":"Oncology"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.ajog.2004.11.018","article-title":"The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers","volume":"192","author":"Chi","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"ref2571","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/OTT.S30238","article-title":"Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options","volume":"6","author":"Elit","year":"2013","journal-title":"OncoTargets Ther"},{"key":"ref5361","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1200\/JCO.2020.38.15_suppl.6039","article-title":"Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial","volume":"38","author":"Lorusso","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref5011","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/annonc\/mdv500","article-title":"Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology\/Gynecologic Oncology Group study","volume":"27","author":"Tewari","year":"2016","journal-title":"Ann Oncol"},{"key":"ref2921","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.1525-1438.2008.01190.x","article-title":"Laparoscopic and laparotomic staging in stage I epithelial ovarian cancer: a comparison of feasibility and safety","volume":"18","author":"Park","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"ref2381","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol Oncol"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/j.ajog.2016.08.030","article-title":"Laparoscopic staging for apparent stage I epithelial ovarian cancer","volume":"216","author":"Melamed","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"ref1711","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(19)32259-7","article-title":"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial","volume":"394","author":"Clamp","year":"2019","journal-title":"Lancet"},{"key":"ref1931","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2009.27.4696","article-title":"Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer","volume":"28","author":"du Bois","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref1311","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.2015.60.9719","article-title":"Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial","volume":"33","author":"Eeles","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref1731","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"ref5061","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"key":"ref2271","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1200\/JCO.2013.53.6524","article-title":"Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study","volume":"32","author":"Burger","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref2881","volume-title":"Gynecologic Oncology Group surgical procedures manual","author":"Whitney","year":"2009"},{"key":"ref4681","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/(SICI)1097-0142(19960215)77:4<733::AID-CNCR20>3.0.CO;2-0","article-title":"Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878","volume":"77","author":"Wadler","year":"1996","journal-title":"Cancer"},{"key":"ref2771","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2016.05.022","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline","volume":"143","author":"Wright","year":"2016","journal-title":"Gynecol Oncol"},{"key":"ref4711","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000227253","article-title":"Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer","volume":"50","author":"Hannigan","year":"1993","journal-title":"Oncology"},{"key":"ref3271","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3747\/co.19.980","article-title":"Management of a suspicious adnexal mass: a clinical practice guideline","volume":"19","author":"Dodge","year":"2012","journal-title":"Curr Oncol"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3802\/jgo.2011.22.3.188","article-title":"Clinicopathologic characteristics of granulosa cell tumors of the ovary: a multicenter retrospective study","volume":"22","author":"Lee","year":"2011","journal-title":"J Gynecol Oncol"},{"key":"ref5241","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3802\/jgo.2015.26.2.156","article-title":"Major clinical research advances in gynecologic cancer in 2014","volume":"26","author":"Suh","year":"2015","journal-title":"J Gynecol Oncol"},{"key":"ref3381","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/ijgc-2019-001172","article-title":"Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey","volume":"30","author":"Greggi","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"ref3701","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ygyno.2018.09.004","article-title":"Analysis of oncologic and reproductive outcomes after fertility-sparing surgery in apparent stage I adult ovarian granulosa cell tumors","volume":"151","author":"Wang","year":"2018","journal-title":"Gynecol Oncol"},{"key":"ref3061","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/j.ajog.2015.10.922","article-title":"Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study","volume":"214","author":"Gueli Alletti","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"ref1361","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/bmj.302.6771.259","article-title":"Hormone replacement therapy and survival after surgery for ovarian cancer","volume":"302","author":"Eeles","year":"1991","journal-title":"BMJ"},{"key":"ref2441","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"ref4541","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"ref4311","first-page":"CD004706","article-title":"Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer","author":"Winter-Roach","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ejso.2013.05.007","article-title":"Laparoscopic staging for apparent early stage ovarian or fallopian tube cancer. First case series from a UK cancer centre and systematic literature review","volume":"39","author":"Brockbank","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1097\/IGC.0000000000000214","article-title":"Laparoscopic and open abdominal staging for early-stage ovarian cancer: our experience, systematic review, and meta-analysis of comparative studies","volume":"24","author":"Bogani","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ygyno.2017.08.013","article-title":"Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base","volume":"147","author":"Nasioudis","year":"2017","journal-title":"Gynecol Oncol"},{"key":"ref4791","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0959-8049(95)00537-4","article-title":"Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study","volume":"32A","author":"Skarlos","year":"1996","journal-title":"Eur J Cancer"},{"key":"ref2321","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1006\/gyno.1994.1220","article-title":"A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer","volume":"54","author":"Kirmani","year":"1994","journal-title":"Gynecol Oncol"},{"key":"ref1491","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJMoa1808424","article-title":"A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms","volume":"380","author":"Harter","year":"2019","journal-title":"N Engl J Med"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1200\/JOP.2017.020818","article-title":"Strategies for introducing outpatient specialty palliative care in gynecologic oncology","volume":"13","author":"Hay","year":"2017","journal-title":"J Oncol Pract"},{"key":"ref3601","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.fertnstert.2020.07.043","article-title":"Reproductive and obstetrical outcomes with the overall survival of fertile-age women treated with fertility-sparing surgery for borderline ovarian tumors in Sweden: a prospective nationwide population-based study","volume":"115","author":"Johansen","year":"2021","journal-title":"Fertil Steril"},{"key":"ref3331","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1245\/s10434-014-3783-6","article-title":"Influence of intraperitoneal dissemination assessed by laparoscopy on prognosis of advanced ovarian cancer: an exploratory analysis of a single-institution experience","volume":"21","author":"Vizzielli","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"ref2651","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br J Cancer"},{"key":"ref161","volume-title":"Gynecologic Oncology Group surgical procedures manual","author":"Whitney","year":"2009"},{"key":"ref1651","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"ref3501","doi-asserted-by":"crossref","first-page":"100071","DOI":"10.1016\/j.eurox.2019.100071","article-title":"Fertility-Sparing surgery for young women with ovarian endometrioid carcinoma: a multicenteric comparative study using inverse probability of treatment weighting","volume":"4","author":"Kajiyama","year":"2019","journal-title":"Eur J Obstet Gynecol Reprod Biol X"},{"key":"ref2151","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ygyno.2009.10.073","article-title":"The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study","volume":"116","author":"Chan","year":"2010","journal-title":"Gynecol Oncol"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ygyno.2018.09.004","article-title":"Analysis of oncologic and reproductive outcomes after fertility-sparing surgery in apparent stage I adult ovarian granulosa cell tumors","volume":"151","author":"Wang","year":"2018","journal-title":"Gynecol Oncol"},{"key":"ref1681","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"ref2451","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ygyno.2014.12.018","article-title":"Distribution and case-fatality ratios by cell-type for ovarian carcinomas: a 22-year series of 562 patients with uniform current histological classification","volume":"136","author":"Seidman","year":"2015","journal-title":"Gynecol Oncol"},{"key":"ref1641","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1023\/A:1008399414923","article-title":"Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument","volume":"11","author":"Trop\u00e9","year":"2000","journal-title":"Ann Oncol"},{"key":"ref2741","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann Oncol"},{"key":"ref3861","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ygyno.2019.06.006","article-title":"The value of surgical staging in patients with apparent early stage epithelial ovarian carcinoma","volume":"154","author":"Hengeveld","year":"2019","journal-title":"Gynecol Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2016.05.022","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline","volume":"143","author":"Wright","year":"2016","journal-title":"Gynecol Oncol"},{"key":"ref2941","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jmig.2008.04.002","article-title":"Laparoscopic treatment and staging of early ovarian cancer","volume":"15","author":"Colomer","year":"2008","journal-title":"J Minim Invasive Gynecol"},{"key":"ref3761","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jso.21079","article-title":"The influence of conservative surgical practices for malignant ovarian germ cell tumors","volume":"98","author":"Chan","year":"2008","journal-title":"J Surg Oncol"},{"key":"ref5151","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2017.08.004","article-title":"An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology\/Gynecologic Oncology Group experience","volume":"147","author":"Oliver","year":"2017","journal-title":"Gynecol Oncol"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/ijgc-2019-001172","article-title":"Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey","volume":"30","author":"Greggi","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"ref1611","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/oxfordjournals.annonc.a059355","article-title":"Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica","volume":"6","author":"Bolis","year":"1995","journal-title":"Ann Oncol"},{"key":"ref3251","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jmig.2009.01.007","article-title":"Laparoscopy and ovarian cancer: a paradigm change in the management of ovarian cancer?","volume":"16","author":"Liu","year":"2009","journal-title":"J Minim Invasive Gynecol"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ygyno.2008.12.034","article-title":"Surgical management of borderline ovarian tumors: the role of fertility-sparing surgery","volume":"113","author":"Park","year":"2009","journal-title":"Gynecol Oncol"},{"key":"ref2791","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the management of ovarian cancer: ASCO guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref3951","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2012.02.024","article-title":"Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining \u2018optimal\u2019 residual disease","volume":"125","author":"Chang","year":"2012","journal-title":"Gynecol Oncol"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ygyno.2013.08.005","article-title":"Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience","volume":"131","author":"Fagotti","year":"2013","journal-title":"Gynecol Oncol"},{"key":"ref3091","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jmig.2017.03.014","article-title":"Impact of surgical route in influencing the risk of lymphatic complications after ovarian cancer staging","volume":"24","author":"Bogani","year":"2017","journal-title":"J Minim Invasive Gynecol"},{"key":"ref1461","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1525-1438.1997.00418.x","article-title":"Systematic pelvic and para-aortic lymphadenectomy in advanced ovarian cancer patients with no residual intraperitoneal disease","volume":"7","author":"Scarabelli","year":"1997","journal-title":"Int J Gynecol Cancer"},{"key":"ref4051","first-page":"67","article-title":"Current management of menopausal symptoms in cancer patients","volume":"16","author":"Barton","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"ref4811","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00001813-199903000-00001","article-title":"Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg","volume":"10","author":"Wils","year":"1999","journal-title":"Anticancer Drugs"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jmig.2016.01.029","article-title":"Laparoscopic management of ovarian cancer patients with localized carcinomatosis and lymph node metastases: results of a retrospective multi-institutional series","volume":"23","author":"Gallotta","year":"2016","journal-title":"J Minim Invasive Gynecol"},{"key":"ref3411","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"ref3921","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref3931","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ygyno.2006.06.028","article-title":"The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer","volume":"103","author":"Eisenhauer","year":"2006","journal-title":"Gynecol Oncol"},{"key":"ref3301","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2407-12-31","article-title":"Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study","volume":"12","author":"Rutten","year":"2012","journal-title":"BMC Cancer"},{"key":"ref4761","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"ref2971","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ygyno.2012.04.018","article-title":"Surgical management of a suspicious adnexal mass: a systematic review","volume":"126","author":"Covens","year":"2012","journal-title":"Gynecol Oncol"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/j.ajog.2015.10.922","article-title":"Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study","volume":"214","author":"Gueli Alletti","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"ref4021","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(00)03590-X","article-title":"Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma","volume":"357","author":"Vergote","year":"2001","journal-title":"Lancet"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.7314\/APJCP.2014.15.12.4909","article-title":"Outcomes of malignant ovarian germ-cell tumors treated in Chiang Mai University Hospital over a nine year period","volume":"15","author":"Neeyalavira","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref2161","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/0090-8258(92)90305-3","article-title":"Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma","volume":"45","author":"Hakes","year":"1992","journal-title":"Gynecol Oncol"},{"key":"ref3531","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/AOG.0000000000002102","article-title":"All-cause mortality after fertility-sparing surgery for stage I epithelial ovarian cancer","volume":"130","author":"Melamed","year":"2017","journal-title":"Obstet Gynecol"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.3802\/jgo.2019.30.e102","article-title":"Prognostic factors and effects of fertility-sparing surgery in women of reproductive age with ovarian clear-cell carcinoma: a propensity score analysis","volume":"30","author":"Yoshihara","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"ref3521","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.3802\/jgo.2017.28.e71","article-title":"Could fertility-sparing surgery be considered for women with early stage ovarian clear cell carcinoma?","volume":"28","author":"Nasioudis","year":"2017","journal-title":"J Gynecol Oncol"},{"key":"ref4321","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/02841860151116420","article-title":"A systematic overview of chemotherapy effects in ovarian cancer","volume":"40","author":"H\u00f6gberg","year":"2001","journal-title":"Acta Oncol"},{"key":"ref4991","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1200\/JCO.2013.53.6524","article-title":"Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study","volume":"32","author":"Burger","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1097\/IGC.0b013e3182a616a7","article-title":"Accuracy and reproducibility of the peritoneal cancer index in advanced ovarian cancer during laparoscopy and laparotomy","volume":"23","author":"Gouy","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"ref3571","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ygyno.2008.12.034","article-title":"Surgical management of borderline ovarian tumors: the role of fertility-sparing surgery","volume":"113","author":"Park","year":"2009","journal-title":"Gynecol Oncol"},{"key":"ref2481","first-page":"2803","article-title":"Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer","volume":"29","author":"Zeimet","year":"2009","journal-title":"Anticancer Res"},{"key":"ref1121","first-page":"949","article-title":"Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma","volume":"80","author":"Soper","year":"1992","journal-title":"Obstet Gynecol"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10397-011-0692-6","article-title":"Increasing experience in laparoscopic staging of early ovarian cancer","volume":"9","author":"Schreuder","year":"2012","journal-title":"Gynecol Surg"},{"key":"ref1991","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000227253","article-title":"Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer","volume":"50","author":"Hannigan","year":"1993","journal-title":"Oncology"},{"key":"ref1781","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1089\/jayao.2016.0086","article-title":"Fertility-sparing surgery should be the standard treatment in patients with malignant ovarian germ cell tumors","volume":"6","author":"Turkmen","year":"2017","journal-title":"J Adolesc Young Adult Oncol"},{"key":"ref2101","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1200\/JCO.2006.09.7527","article-title":"Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar\/AIO and EBMT","volume":"25","author":"M\u00f6bus","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref5141","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-8258(03)00377-9","article-title":"First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up","volume":"90","author":"Fujiwara","year":"2003","journal-title":"Gynecol Oncol"},{"key":"ref3041","first-page":"766","article-title":"A novel surgical technique for the large ovarian cystic mass - combined mini-laparotomy and laparoscopy","volume":"37","author":"Li","year":"2016","journal-title":"Eur J Gynaecol Oncol"},{"key":"ref4191","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/jnci\/dji102","article-title":"Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial","volume":"97","author":"Panici","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"ref2471","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ygyno.2011.05.022","article-title":"Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer","volume":"122","author":"Landrum","year":"2011","journal-title":"Gynecol Oncol"},{"key":"ref1031","first-page":"898","article-title":"[Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery]","volume":"47","author":"Yang","year":"2012","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"ref3291","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2009.09.015","article-title":"Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery?","volume":"116","author":"Fagotti","year":"2010","journal-title":"Gynecol Oncol"},{"key":"ref3641","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.7314\/APJCP.2014.15.12.4909","article-title":"Outcomes of malignant ovarian germ-cell tumors treated in Chiang Mai University Hospital over a nine year period","volume":"15","author":"Neeyalavira","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/IGC.0000000000001328","article-title":"Clinical outcome after completion surgery in patients with ovarian cancer: the charite experience","volume":"28","author":"Babayeva","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"ref2001","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1200\/JCO.1992.10.5.718","article-title":"Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group","volume":"10","author":"Swenerton","year":"1992","journal-title":"J Clin Oncol"},{"key":"ref3001","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1097\/IGC.0b013e3182a616a7","article-title":"Accuracy and reproducibility of the peritoneal cancer index in advanced ovarian cancer during laparoscopy and laparotomy","volume":"23","author":"Gouy","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"ref2531","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref2631","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1200\/JCO.20.00799","article-title":"Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial","volume":"38","author":"DiSilvestro","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref4931","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2015.07.103","article-title":"Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology\/GOG study","volume":"139","author":"Ferriss","year":"2015","journal-title":"Gynecol Oncol"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jmig.2017.03.014","article-title":"Impact of surgical route in influencing the risk of lymphatic complications after ovarian cancer staging","volume":"24","author":"Bogani","year":"2017","journal-title":"J Minim Invasive Gynecol"},{"key":"ref3831","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0029-7844(96)00021-X","article-title":"Laparotomy to complete staging of presumed early ovarian cancer","volume":"87","author":"Stier","year":"1996","journal-title":"Obstet Gynecol"},{"key":"ref4141","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10147-012-0483-8","article-title":"Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group","volume":"18","author":"Oshita","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"ref2051","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1002\/cncr.24461","article-title":"Fertility preservation in young women with epithelial ovarian cancer","volume":"115","author":"Wright","year":"2009","journal-title":"Cancer"},{"key":"ref1911","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2018.07.021","article-title":"Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology\/Gynecologic Oncology Group study","volume":"151","author":"Olawaiye","year":"2018","journal-title":"Gynecol Oncol"},{"key":"ref3621","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3802\/jgo.2011.22.3.188","article-title":"Clinicopathologic characteristics of granulosa cell tumors of the ovary: a multicenter retrospective study","volume":"22","author":"Lee","year":"2011","journal-title":"J Gynecol Oncol"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11701-018-0838-x","article-title":"Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis","volume":"13","author":"Cardenas-Goicoechea","year":"2019","journal-title":"J Robot Surg"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jso.21079","article-title":"The influence of conservative surgical practices for malignant ovarian germ cell tumors","volume":"98","author":"Chan","year":"2008","journal-title":"J Surg Oncol"},{"key":"ref3851","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10397-011-0692-6","article-title":"Increasing experience in laparoscopic staging of early ovarian cancer","volume":"9","author":"Schreuder","year":"2012","journal-title":"Gynecol Surg"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12885-020-06828-y","article-title":"Fertility sparing surgery vs radical surgery for epithelial ovarian cancer: a meta-analysis of overall survival and disease-free survival","volume":"20","author":"Liu","year":"2020","journal-title":"BMC Cancer"},{"key":"ref2071","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0959-8049(95)00537-4","article-title":"Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study","volume":"32A","author":"Skarlos","year":"1996","journal-title":"Eur J Cancer"},{"key":"ref5301","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref2561","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"ref4261","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2009.03.020","article-title":"Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy","volume":"114","author":"Aletti","year":"2009","journal-title":"Gynecol Oncol"},{"key":"ref4201","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/bjc.2012.336","article-title":"Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial","volume":"107","author":"Dell\u2019 Anna","year":"2012","journal-title":"Br J Cancer"},{"key":"ref3371","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/AOG.0000000000002796","article-title":"Laparoscopic surgical algorithm to triage the timing of tumor reductive surgery in advanced ovarian cancer","volume":"132","author":"Fleming","year":"2018","journal-title":"Obstet Gynecol"},{"key":"ref2191","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"ref3241","first-page":"103","article-title":"[Clinical comparative analysis of comprehensive laparoscopic and laparotomic staging of early-stage epithelial ovarian cancer]","volume":"52","author":"Xiong","year":"2017","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"ref4671","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1093\/annonc\/mds060","article-title":"First-line treatment of advanced ovarian cancer with paclitaxel\/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG","volume":"23","author":"Lindemann","year":"2012","journal-title":"Ann Oncol"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jmig.2009.01.007","article-title":"Laparoscopy and ovarian cancer: a paradigm change in the management of ovarian cancer?","volume":"16","author":"Liu","year":"2009","journal-title":"J Minim Invasive Gynecol"},{"key":"ref3341","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.2016.69.2962","article-title":"Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer: a randomized controlled trial","volume":"35","author":"Rutten","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref1171","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/annonc\/mdw563","article-title":"The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study","volume":"28","author":"Mangili","year":"2017","journal-title":"Ann Oncol"},{"key":"ref5051","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/gyno.1999.5677","article-title":"Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest","volume":"76","author":"Gadducci","year":"2000","journal-title":"Gynecol Oncol"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ygyno.2017.06.019","article-title":"Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer","volume":"146","author":"van de Vrie","year":"2017","journal-title":"Gynecol Oncol"},{"key":"ref4081","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/bmj.302.6771.259","article-title":"Hormone replacement therapy and survival after surgery for ovarian cancer","volume":"302","author":"Eeles","year":"1991","journal-title":"BMJ"},{"key":"ref2011","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1200\/JCO.1994.12.10.2066","article-title":"Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer","volume":"12","author":"Taylor","year":"1994","journal-title":"J Clin Oncol"},{"key":"ref2411","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology\/Gynecologic Oncology Group study","volume":"37","author":"Walker","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref1341","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3949\/ccjm.75.Suppl_4.S17","article-title":"Update on nonhormonal approaches to menopausal management","volume":"75","author":"Jenkins","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"ref2171","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1023\/A:1008256431090","article-title":"A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study","volume":"8","author":"Lambert","year":"1997","journal-title":"Ann Oncol"},{"key":"ref4301","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199004123221501","article-title":"Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials","volume":"322","author":"Young","year":"1990","journal-title":"N Engl J Med"},{"key":"ref5001","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2015.08.011","article-title":"Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology\/gynecologic oncology group study (ADS-1236)","volume":"139","author":"Duska","year":"2015","journal-title":"Gynecol Oncol"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejogrb.2016.03.029","article-title":"Laparoscopic surgical staging in women with early stage epithelial ovarian cancer performed by recently certified gynecologic oncologists","volume":"201","author":"Minig","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref1521","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/jjco\/hyw068","article-title":"The effect of lymphadenectomy on survival and recurrence in patients with ovarian cancer: a systematic review and meta-analysis","volume":"46","author":"Zhou","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"ref5091","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41416-019-0543-1","article-title":"Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study","volume":"121","author":"Shi","year":"2019","journal-title":"Br J Cancer"},{"key":"ref2661","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","article-title":"Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents","volume":"2","author":"Birkbak","year":"2012","journal-title":"Cancer Discov"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12957-017-1222-4","article-title":"Oncofertility in patients with stage I epithelial ovarian cancer: fertility-sparing surgery in young women of reproductive age","volume":"15","author":"Jiang","year":"2017","journal-title":"World J Surg Oncol"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s00464-013-3390-9","article-title":"Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience","volume":"28","author":"Gallotta","year":"2014","journal-title":"Surg Endosc"},{"key":"ref4381","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2012.02.024","article-title":"Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining \u2018optimal\u2019 residual disease","volume":"125","author":"Chang","year":"2012","journal-title":"Gynecol Oncol"},{"key":"ref3081","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ygyno.2016.07.003","article-title":"Interval laparoscopic en-bloc resection of the pelvis (L-EnBRP) in patients with stage IIIC-IV ovarian cancer: description of the technique and surgical outcomes","volume":"142","author":"Tozzi","year":"2016","journal-title":"Gynecol Oncol"},{"key":"ref3591","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13048-018-0423-y","article-title":"Age-dependent difference in impact of fertility preserving surgery on disease-specific survival in women with stage I borderline ovarian tumors","volume":"11","author":"Sun","year":"2018","journal-title":"J Ovarian Res"},{"key":"ref3161","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/jcm9082507","article-title":"Three and five-year mortality in ovarian cancer after minimally invasive compared with open surgery: a systematic review and meta-analysis","volume":"9","author":"Jochum","year":"2020","journal-title":"J Clin Med"},{"key":"ref4531","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref1981","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.1992.10.5.706","article-title":"Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer","volume":"10","author":"Alberts","year":"1992","journal-title":"J Clin Oncol"},{"key":"ref4231","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/IGC.0b013e3181d6de1d","article-title":"Systematic lymphadenectomy for survival in epithelial ovarian cancer: a meta-analysis","volume":"20","author":"Kim","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"ref4281","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1200\/EDBK_158927","article-title":"Update on intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer","volume":"35","author":"Gourley","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ygyno.2015.02.021","article-title":"Improving quality and decreasing cost in gynecologic oncology care. Society of gynecologic oncology recommendations for clinical practice","volume":"137","author":"Rimel","year":"2015","journal-title":"Gynecol Oncol"},{"key":"ref4731","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1200\/JCO.1994.12.10.2066","article-title":"Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer","volume":"12","author":"Taylor","year":"1994","journal-title":"J Clin Oncol"},{"key":"ref4461","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol"},{"key":"ref211","first-page":"CD005344","article-title":"Laparoscopy versus laparotomy for FIGO Stage I ovarian cancer","author":"Medeiros","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"ref1411","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/aogs.12322","article-title":"Lymphadenectomy in surgical stage I epithelial ovarian cancer","volume":"93","author":"Svolgaard","year":"2014","journal-title":"Acta Obstet Gynecol Scand"},{"key":"ref4941","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref1441","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1477-7819-8-106","article-title":"Lymph node metastasis in grossly apparent clinical stage Ia epithelial ovarian cancer: Hacettepe experience and review of literature","volume":"8","author":"Desteli","year":"2010","journal-title":"World J Surg Oncol"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4103\/ijc.IJC_306_17","article-title":"Role of laparoscopy in predicting surgical outcomes in patients undergoing interval cytoreduction surgery for advanced ovarian carcinoma: A prospective validation study","volume":"54","author":"Tomar","year":"2017","journal-title":"Indian J Cancer"},{"key":"ref3771","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/IGC.0b013e31819d82c3","article-title":"Long-term survival after fertility-sparing surgery for epithelial ovarian cancer","volume":"19","author":"Schlaerth","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"ref4871","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ygyno.2009.10.073","article-title":"The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study","volume":"116","author":"Chan","year":"2010","journal-title":"Gynecol Oncol"},{"key":"ref2721","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ygyno.2014.02.006","article-title":"Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center","volume":"133","author":"Erickson","year":"2014","journal-title":"Gynecol Oncol"},{"key":"ref4501","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"ref3961","first-page":"CD007565","article-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer","author":"Elattar","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/ijgc-2020-001716","article-title":"Fertility sparing surgery for patients with FIGO stage I clear cell ovarian carcinoma: a database analysis and systematic review of the literature","volume":"30","author":"Nasioudis","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"ref2301","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2012.11.038","article-title":"Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study","volume":"128","author":"Monk","year":"2013","journal-title":"Gynecol Oncol"},{"key":"ref3721","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.suronc.2019.08.006","article-title":"Clinical management of malignant ovarian germ cell tumors: a 26-year experience in a tertiary care institution","volume":"31","author":"Hu","year":"2019","journal-title":"Surg Oncol"},{"key":"ref4391","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"ref4621","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ygyno.2014.02.006","article-title":"Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center","volume":"133","author":"Erickson","year":"2014","journal-title":"Gynecol Oncol"},{"key":"ref2401","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.3802\/jgo.2017.28.e71","article-title":"Could fertility-sparing surgery be considered for women with early stage ovarian clear cell carcinoma?","volume":"28","author":"Nasioudis","year":"2017","journal-title":"J Gynecol Oncol"},{"key":"ref2121","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1200\/JCO.2006.10.3846","article-title":"Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Spriggs","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref1301","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(00)03590-X","article-title":"Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma","volume":"357","author":"Vergote","year":"2001","journal-title":"Lancet"},{"key":"ref1371","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/sj.bjc.6603323","article-title":"Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis","volume":"95","author":"Maggioni","year":"2006","journal-title":"Br J Cancer"},{"key":"ref2251","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG Oncology\/Gynecologic Oncology Group study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin Cancer Res"},{"key":"ref1771","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial","volume":"29","author":"Pignata","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref1471","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/jnci\/dji102","article-title":"Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial","volume":"97","author":"Panici","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"ref5031","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1470-2045(12)70567-3","article-title":"Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial","volume":"14","author":"Stark","year":"2013","journal-title":"Lancet Oncol"},{"key":"ref3491","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.3802\/jgo.2019.30.e102","article-title":"Prognostic factors and effects of fertility-sparing surgery in women of reproductive age with ovarian clear-cell carcinoma: a propensity score analysis","volume":"30","author":"Yoshihara","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"ref2811","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ygyno.2015.02.021","article-title":"Improving quality and decreasing cost in gynecologic oncology care. Society of gynecologic oncology recommendations for clinical practice","volume":"137","author":"Rimel","year":"2015","journal-title":"Gynecol Oncol"},{"key":"ref4251","volume-title":"Gynecologic Oncology Group surgical procedures manual","author":"Whitney","year":"2010"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1525-1438.2006.00303.x","article-title":"Impact of initial surgical access on staging and survival of patients with stage I ovarian cancer","volume":"16","author":"L\u00e9curu","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"ref5411","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40364-015-0033-4","article-title":"Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs","volume":"3","author":"Marquard","year":"2015","journal-title":"Biomark Res"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1016\/j.ejca.2013.06.013","article-title":"Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial","volume":"49","author":"van Meurs","year":"2013","journal-title":"Eur J Cancer"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1074-3804(05)60481-1","article-title":"Laparoscopic surgery for complex ovarian masses","volume":"7","author":"Ulrich","year":"2000","journal-title":"J Am Assoc Gynecol Laparosc"},{"key":"ref3711","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00404-019-05160-6","article-title":"Prognostic factors and oncological outcomes of ovarian yolk sac tumors: a retrospective multicentric analysis of 99 cases","volume":"300","author":"Boyraz","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"ref1631","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jnci\/95.2.113","article-title":"Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial","volume":"95","author":"Trimbos","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"ref2181","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"ref4361","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1023\/A:1008399414923","article-title":"Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument","volume":"11","author":"Trop\u00e9","year":"2000","journal-title":"Ann Oncol"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4293\/JSLS.2014.00232","article-title":"Laparoscopy-assisted supracervical hysterectomy for ovarian cancer: cervical recurrence","volume":"18","author":"Fanning","year":"2014","journal-title":"JSLS"},{"key":"ref3111","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/j.ajog.2016.08.030","article-title":"Laparoscopic staging for apparent stage I epithelial ovarian cancer","volume":"216","author":"Melamed","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"ref4521","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer","volume":"18","author":"Neijt","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref5231","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"ref1401","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1245\/s10434-012-2439-7","article-title":"Systematic para-aortic and pelvic lymphadenectomy in early stage epithelial ovarian cancer: a prospective study","volume":"19","author":"Ditto","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ygyno.2012.04.018","article-title":"Surgical management of a suspicious adnexal mass: a systematic review","volume":"126","author":"Covens","year":"2012","journal-title":"Gynecol Oncol"},{"key":"ref3231","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejogrb.2016.03.029","article-title":"Laparoscopic surgical staging in women with early stage epithelial ovarian cancer performed by recently certified gynecologic oncologists","volume":"201","author":"Minig","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref2581","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref3121","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jmig.2016.11.004","article-title":"Robotic versus laparoscopic staging for early ovarian cancer: a case-matched control study","volume":"24","author":"Gallotta","year":"2017","journal-title":"J Minim Invasive Gynecol"},{"key":"ref3351","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4103\/ijc.IJC_306_17","article-title":"Role of laparoscopy in predicting surgical outcomes in patients undergoing interval cytoreduction surgery for advanced ovarian carcinoma: A prospective validation study","volume":"54","author":"Tomar","year":"2017","journal-title":"Indian J Cancer"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/jcm9082507","article-title":"Three and five-year mortality in ovarian cancer after minimally invasive compared with open surgery: a systematic review and meta-analysis","volume":"9","author":"Jochum","year":"2020","journal-title":"J Clin Med"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/AOG.0000000000002102","article-title":"All-cause mortality after fertility-sparing surgery for stage I epithelial ovarian cancer","volume":"130","author":"Melamed","year":"2017","journal-title":"Obstet Gynecol"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2009.09.015","article-title":"Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery?","volume":"116","author":"Fagotti","year":"2010","journal-title":"Gynecol Oncol"},{"key":"ref4431","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(19)32259-7","article-title":"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial","volume":"394","author":"Clamp","year":"2019","journal-title":"Lancet"},{"key":"ref4771","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"ref5181","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ygyno.2012.03.027","article-title":"Progression-free and overall survival of a modified outpatient regimen of primary intravenous\/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer","volume":"125","author":"Barlin","year":"2012","journal-title":"Gynecol Oncol"},{"key":"ref1721","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1470-2045(20)30218-7","article-title":"Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial","volume":"21","author":"Blagden","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref2331","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/gyno.1999.5677","article-title":"Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest","volume":"76","author":"Gadducci","year":"2000","journal-title":"Gynecol Oncol"},{"key":"ref3281","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/j.ajog.2008.06.052","article-title":"Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma","volume":"199","author":"Fagotti","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"ref3741","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2020.01.033","article-title":"Trends in the surgical management of malignant ovarian germcell tumors","volume":"157","author":"Nasioudis","year":"2020","journal-title":"Gynecol Oncol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.2016.70.1474","article-title":"Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Ferrell","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref3141","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00404-018-4709-5","article-title":"Report of the survey on current opinions and practice of German Society for Gynecologic Endoscopy (AGE) members regarding the laparoscopic treatment of ovarian malignancies","volume":"297","author":"Radosa","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ajog.2013.04.013","article-title":"Staging laparoscopy for the management of early-stage ovarian cancer: a metaanalysis","volume":"209","author":"Park","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/j.ajog.2008.06.052","article-title":"Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma","volume":"199","author":"Fagotti","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"ref1431","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/IGC.0000000000000787","article-title":"Incidence of lymph node metastases in apparent early-stage low-grade epithelial ovarian cancer: a comprehensive review","volume":"26","author":"Lago","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"ref1531","volume-title":"Gynecologic Oncology Group surgical procedures manual","author":"Whitney","year":"2010"},{"key":"ref2821","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1200\/JOP.2017.020818","article-title":"Strategies for introducing outpatient specialty palliative care in gynecologic oncology","volume":"13","author":"Hay","year":"2017","journal-title":"J Oncol Pract"},{"key":"ref2241","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2018.08.036","article-title":"Exploratory outcome analyses according to stage and\/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer","volume":"152","author":"Gonz\u00e1lez Mart\u00edn","year":"2019","journal-title":"Gynecol Oncol"},{"key":"ref1241","first-page":"CD007565","article-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer","author":"Elattar","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"ref4961","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2018.08.036","article-title":"Exploratory outcome analyses according to stage and\/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer","volume":"152","author":"Gonz\u00e1lez Mart\u00edn","year":"2019","journal-title":"Gynecol Oncol"},{"key":"ref4411","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.3747\/co.23.3200","article-title":"Sensor-controlled scalp cooling to prevent chemotherapy-induced alopecia in female cancer patients","volume":"23","author":"Fehr","year":"2016","journal-title":"Curr Oncol"},{"key":"ref4861","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ygyno.2006.06.013","article-title":"Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study","volume":"102","author":"Bell","year":"2006","journal-title":"Gynecol Oncol"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.fertnstert.2020.07.043","article-title":"Reproductive and obstetrical outcomes with the overall survival of fertile-age women treated with fertility-sparing surgery for borderline ovarian tumors in Sweden: a prospective nationwide population-based study","volume":"115","author":"Johansen","year":"2021","journal-title":"Fertil Steril"},{"key":"ref2641","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1200\/JCO.2020.38.15_suppl.6039","article-title":"Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial","volume":"38","author":"Lorusso","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref5081","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41416-018-0036-7","article-title":"Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial","volume":"119","author":"Shi","year":"2018","journal-title":"Br J Cancer"},{"key":"ref3731","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000381771","article-title":"An analysis of prognostic factors in patients with ovarian malignant germ cell tumors who are treated with fertility-preserving surgery","volume":"81","author":"Yang","year":"2016","journal-title":"Gynecol Obstet Invest"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/IGC.0b013e31819d82c3","article-title":"Long-term survival after fertility-sparing surgery for epithelial ovarian cancer","volume":"19","author":"Schlaerth","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"ref4821","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1200\/JCO.2006.09.7527","article-title":"Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar\/AIO and EBMT","volume":"25","author":"M\u00f6bus","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.suronc.2019.08.006","article-title":"Clinical management of malignant ovarian germ cell tumors: a 26-year experience in a tertiary care institution","volume":"31","author":"Hu","year":"2019","journal-title":"Surg Oncol"},{"key":"ref4841","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1200\/JCO.2006.10.3846","article-title":"Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Spriggs","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref1961","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/(SICI)1097-0142(19960215)77:4<733::AID-CNCR20>3.0.CO;2-0","article-title":"Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878","volume":"77","author":"Wadler","year":"1996","journal-title":"Cancer"},{"key":"ref3431","first-page":"209","article-title":"Application of combined intraperitoneal and intravenous neoadjuvant chemotherapy in senile patients with advanced ovarian cancer and massive ascites","volume":"38","author":"Liu","year":"2017","journal-title":"Eur J Gynaecol Oncol"},{"key":"ref5101","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol Oncol"},{"key":"ref2391","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2013.04.001","article-title":"Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study","volume":"130","author":"Landrum","year":"2013","journal-title":"Gynecol Oncol"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.1471-0528.2008.01775.x","article-title":"Should adnexal mass size influence surgical approach? A series of 186 laparoscopically managed large adnexal masses","volume":"115","author":"Ghezzi","year":"2008","journal-title":"BJOG"},{"key":"ref1661","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"ref2141","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ygyno.2006.06.013","article-title":"Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study","volume":"102","author":"Bell","year":"2006","journal-title":"Gynecol Oncol"},{"key":"ref2911","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1245\/s10434-008-9893-2","article-title":"Comparison of laparoscopy and laparotomy in surgical staging of early-stage ovarian and fallopian tubal cancer","volume":"15","author":"Park","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"ref5171","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ygyno.2014.12.018","article-title":"Distribution and case-fatality ratios by cell-type for ovarian carcinomas: a 22-year series of 562 patients with uniform current histological classification","volume":"136","author":"Seidman","year":"2015","journal-title":"Gynecol Oncol"},{"key":"ref721","first-page":"400","article-title":"Fertility preservation in women","volume":"378","author":"Donnez","year":"2018","journal-title":"N Engl J Med"},{"key":"ref3021","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000381462","article-title":"Oncologic concerns regarding laparoscopic cytoreductive surgery in patients with advanced ovarian cancer submitted to neoadjuvant chemotherapy","volume":"89","author":"Favero","year":"2015","journal-title":"Oncology"},{"key":"ref2961","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4293\/108680810X12785289143990","article-title":"The safety and efficacy of laparoscopic surgical staging and debulking of apparent advanced stage ovarian, fallopian tube, and primary peritoneal cancers","volume":"14","author":"Nezhat","year":"2010","journal-title":"JSLS"},{"key":"ref2591","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br J Cancer"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jmig.2019.06.017","article-title":"Mortality rates in laparoscopic and robotic gynecologic oncology surgery: a systemic review and meta-analysis","volume":"26","author":"Behbehani","year":"2019","journal-title":"J Minim Invasive Gynecol"},{"key":"ref2671","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","article-title":"Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation","volume":"72","author":"Popova","year":"2012","journal-title":"Cancer Res"},{"key":"ref4511","first-page":"S15","article-title":"Paclitaxel (175 mg\/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis","volume":"24","author":"Neijt","year":"1997","journal-title":"Semin Oncol"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/GRF.0b013e318248045b","article-title":"Treatment of ovarian cancer in young women","volume":"55","author":"Gershenson","year":"2012","journal-title":"Clin Obstet Gynecol"},{"key":"ref2201","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref4171","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1006\/gyno.1995.1059","article-title":"Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival","volume":"56","author":"Scarabelli","year":"1995","journal-title":"Gynecol Oncol"},{"key":"ref4011","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ygyno.2007.10.022","article-title":"The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer","volume":"108","author":"Eisenhauer","year":"2008","journal-title":"Gynecol Oncol"},{"key":"ref3321","doi-asserted-by":"crossref","first-page":"462.e1","DOI":"10.1016\/j.ajog.2013.07.016","article-title":"A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer","volume":"209","author":"Fagotti","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"ref4561","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/annonc\/mdl401","article-title":"Feasibility, toxicity and quality of life of first-line chemotherapy with platinum\/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany","volume":"18","author":"Hilpert","year":"2007","journal-title":"Ann Oncol"},{"key":"ref5021","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2012.11.038","article-title":"Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study","volume":"128","author":"Monk","year":"2013","journal-title":"Gynecol Oncol"},{"key":"ref1451","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1006\/gyno.1995.1059","article-title":"Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival","volume":"56","author":"Scarabelli","year":"1995","journal-title":"Gynecol Oncol"},{"key":"ref4091","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/sj.bjc.6603323","article-title":"Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis","volume":"95","author":"Maggioni","year":"2006","journal-title":"Br J Cancer"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jmig.2017.02.013","article-title":"Minimally invasive surgical staging in early-stage ovarian carcinoma: a systematic review and meta-analysis","volume":"24","author":"Bogani","year":"2017","journal-title":"J Minim Invasive Gynecol"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ygyno.2019.06.006","article-title":"The value of surgical staging in patients with apparent early stage epithelial ovarian carcinoma","volume":"154","author":"Hengeveld","year":"2019","journal-title":"Gynecol Oncol"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/bjc.2016.254","article-title":"Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer","volume":"115","author":"Fruscio","year":"2016","journal-title":"Br J Cancer"},{"key":"ref4641","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1016\/j.ejca.2010.06.124","article-title":"Paclitaxel\/carboplatin versus topotecan\/paclitaxel\/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study","volume":"46","author":"Bolis","year":"2010","journal-title":"Eur J Cancer"},{"key":"ref4131","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/aogs.12322","article-title":"Lymphadenectomy in surgical stage I epithelial ovarian cancer","volume":"93","author":"Svolgaard","year":"2014","journal-title":"Acta Obstet Gynecol Scand"},{"key":"ref1481","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/bjc.2012.336","article-title":"Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial","volume":"107","author":"Dell\u2019 Anna","year":"2012","journal-title":"Br J Cancer"},{"key":"ref1831","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2005.02.4067","article-title":"Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin\/paclitaxel versus carboplatin\/paclitaxel","volume":"24","author":"Greimel","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref4691","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref4491","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial","volume":"29","author":"Pignata","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref1161","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jpedsurg.2003.11.027","article-title":"Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study","volume":"39","author":"Billmire","year":"2004","journal-title":"J Pediatr Surg"},{"key":"ref2521","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3802\/jgo.2015.26.2.156","article-title":"Major clinical research advances in gynecologic cancer in 2014","volume":"26","author":"Suh","year":"2015","journal-title":"J Gynecol Oncol"},{"key":"ref4371","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"ref4651","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2009.27.4696","article-title":"Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer","volume":"28","author":"du Bois","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.2016.69.2962","article-title":"Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer: a randomized controlled trial","volume":"35","author":"Rutten","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref3981","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol Oncol"},{"key":"ref2871","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.hoc.2011.10.004","article-title":"Current surgical management of ovarian cancer","volume":"26","author":"Schorge","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"e3655","DOI":"10.1097\/MD.0000000000003655","article-title":"Comparison of laparoscopy and laparotomy in surgical staging of apparent early ovarian cancer: 13-year experience","volume":"95","author":"Lu","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"ref3791","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.2007.11.0932","article-title":"Role of surgery in ovarian carcinoma","volume":"25","author":"Fader","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref3891","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/annonc\/mdw563","article-title":"The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study","volume":"28","author":"Mangili","year":"2017","journal-title":"Ann Oncol"},{"key":"ref1271","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"key":"ref1591","first-page":"CD004706","article-title":"Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer","author":"Winter-Roach","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jmig.2016.11.004","article-title":"Robotic versus laparoscopic staging for early ovarian cancer: a case-matched control study","volume":"24","author":"Gallotta","year":"2017","journal-title":"J Minim Invasive Gynecol"},{"key":"ref5351","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1200\/JCO.20.00799","article-title":"Efficacy of maintenance olaparib for patients with newly diagnosed advanced ovarian cancer with a BRCA mutation: subgroup analysis findings from the SOLO1 trial","volume":"38","author":"DiSilvestro","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ygyno.2016.07.003","article-title":"Interval laparoscopic en-bloc resection of the pelvis (L-EnBRP) in patients with stage IIIC-IV ovarian cancer: description of the technique and surgical outcomes","volume":"142","author":"Tozzi","year":"2016","journal-title":"Gynecol Oncol"},{"key":"ref3031","doi-asserted-by":"crossref","first-page":"e3655","DOI":"10.1097\/MD.0000000000003655","article-title":"Comparison of laparoscopy and laparotomy in surgical staging of apparent early ovarian cancer: 13-year experience","volume":"95","author":"Lu","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"ref2211","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2015.07.103","article-title":"Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology\/GOG study","volume":"139","author":"Ferriss","year":"2015","journal-title":"Gynecol Oncol"},{"key":"ref1691","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.3747\/co.23.3200","article-title":"Sensor-controlled scalp cooling to prevent chemotherapy-induced alopecia in female cancer patients","volume":"23","author":"Fehr","year":"2016","journal-title":"Curr Oncol"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.rbmo.2018.03.018","article-title":"Survival of selected patients with ovarian cancer treated with fertility-sparing surgery","volume":"37","author":"Hedb\u00e4ck","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"ref3821","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/GRF.0b013e318248045b","article-title":"Treatment of ovarian cancer in young women","volume":"55","author":"Gershenson","year":"2012","journal-title":"Clin Obstet Gynecol"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.2007.11.0932","article-title":"Role of surgery in ovarian carcinoma","volume":"25","author":"Fader","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref1541","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2009.03.020","article-title":"Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy","volume":"114","author":"Aletti","year":"2009","journal-title":"Gynecol Oncol"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000381771","article-title":"An analysis of prognostic factors in patients with ovarian malignant germ cell tumors who are treated with fertility-preserving surgery","volume":"81","author":"Yang","year":"2016","journal-title":"Gynecol Obstet Invest"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1200\/JCO.2009.24.8617","article-title":"Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection","volume":"28","author":"Satoh","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref2731","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jamcollsurg.2015.01.056","article-title":"Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival","volume":"220","author":"Bristow","year":"2015","journal-title":"J Am Coll Surg"},{"key":"ref2461","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ygyno.2012.03.027","article-title":"Progression-free and overall survival of a modified outpatient regimen of primary intravenous\/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer","volume":"125","author":"Barlin","year":"2012","journal-title":"Gynecol Oncol"},{"key":"ref1791","first-page":"S15","article-title":"Paclitaxel (175 mg\/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis","volume":"24","author":"Neijt","year":"1997","journal-title":"Semin Oncol"},{"key":"ref5401","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/s13058-014-0475-x","article-title":"Association of BRCA1\/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes","volume":"16","author":"Timms","year":"2014","journal-title":"Breast Cancer Res"},{"key":"ref1561","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1200\/EDBK_158927","article-title":"Update on intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer","volume":"35","author":"Gourley","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref321","first-page":"766","article-title":"A novel surgical technique for the large ovarian cystic mass - combined mini-laparotomy and laparoscopy","volume":"37","author":"Li","year":"2016","journal-title":"Eur J Gynaecol Oncol"},{"key":"ref1571","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"ref4951","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.5517","article-title":"Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology\/Gynecologic Oncology Group (GOG) study [abstract]","volume":"36","author":"Burger","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref1801","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer","volume":"18","author":"Neijt","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref5381","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","article-title":"Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents","volume":"2","author":"Birkbak","year":"2012","journal-title":"Cancer Discov"},{"key":"ref1841","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/annonc\/mdl401","article-title":"Feasibility, toxicity and quality of life of first-line chemotherapy with platinum\/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany","volume":"18","author":"Hilpert","year":"2007","journal-title":"Ann Oncol"},{"key":"ref1421","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10147-012-0483-8","article-title":"Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group","volume":"18","author":"Oshita","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"ref2551","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref1511","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/IGC.0b013e3181d6de1d","article-title":"Systematic lymphadenectomy for survival in epithelial ovarian cancer: a meta-analysis","volume":"20","author":"Kim","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"ref2431","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2017.08.004","article-title":"An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology\/Gynecologic Oncology Group experience","volume":"147","author":"Oliver","year":"2017","journal-title":"Gynecol Oncol"},{"key":"ref3651","first-page":"1001","article-title":"A Long-term follow-up study of 91 cases with ovarian granulosa cell tumors","volume":"34","author":"Shim","year":"2014","journal-title":"Anticancer Res"},{"key":"ref2281","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2015.08.011","article-title":"Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology\/gynecologic oncology group study (ADS-1236)","volume":"139","author":"Duska","year":"2015","journal-title":"Gynecol Oncol"},{"key":"ref2291","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/annonc\/mdv500","article-title":"Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology\/Gynecologic Oncology Group study","volume":"27","author":"Tewari","year":"2016","journal-title":"Ann Oncol"},{"key":"ref1251","first-page":"928","article-title":"Cytoreductive surgery for advanced ovarian cancer: quo vadis?","volume":"25","author":"Schorge","year":"2011","journal-title":"Oncology (Williston Park)"},{"key":"ref3871","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/IGC.0000000000001328","article-title":"Clinical outcome after completion surgery in patients with ovarian cancer: the charite experience","volume":"28","author":"Babayeva","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"ref4611","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djj296","article-title":"Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO","volume":"98","author":"Pfisterer","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"ref3551","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/bjc.2016.254","article-title":"Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer","volume":"115","author":"Fruscio","year":"2016","journal-title":"Br J Cancer"},{"key":"ref4121","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1245\/s10434-012-2439-7","article-title":"Systematic para-aortic and pelvic lymphadenectomy in early stage epithelial ovarian cancer: a prospective study","volume":"19","author":"Ditto","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"ref4331","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/oxfordjournals.annonc.a059355","article-title":"Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica","volume":"6","author":"Bolis","year":"1995","journal-title":"Ann Oncol"},{"key":"ref711","first-page":"209","article-title":"Application of combined intraperitoneal and intravenous neoadjuvant chemotherapy in senile patients with advanced ovarian cancer and massive ascites","volume":"38","author":"Liu","year":"2017","journal-title":"Eur J Gynaecol Oncol"},{"key":"ref5111","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2013.04.001","article-title":"Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study","volume":"130","author":"Landrum","year":"2013","journal-title":"Gynecol Oncol"},{"key":"ref3541","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12957-017-1222-4","article-title":"Oncofertility in patients with stage I epithelial ovarian cancer: fertility-sparing surgery in young women of reproductive age","volume":"15","author":"Jiang","year":"2017","journal-title":"World J Surg Oncol"},{"key":"ref2491","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1758834010361333","article-title":"Practical considerations in ovarian cancer chemotherapy","volume":"2","author":"Cristea","year":"2010","journal-title":"Ther Adv Med Oncol"},{"key":"ref3901","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1245\/s10434-016-5234-z","article-title":"Significance of the complete surgical staging of stage I malignant ovarian germ cell tumors","volume":"23","author":"Park","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"ref5251","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jmig.2008.04.002","article-title":"Laparoscopic treatment and staging of early ovarian cancer","volume":"15","author":"Colomer","year":"2008","journal-title":"J Minim Invasive Gynecol"},{"key":"ref5211","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1758834010361333","article-title":"Practical considerations in ovarian cancer chemotherapy","volume":"2","author":"Cristea","year":"2010","journal-title":"Ther Adv Med Oncol"},{"key":"ref2361","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41416-018-0036-7","article-title":"Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial","volume":"119","author":"Shi","year":"2018","journal-title":"Br J Cancer"},{"key":"ref4161","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1477-7819-8-106","article-title":"Lymph node metastasis in grossly apparent clinical stage Ia epithelial ovarian cancer: Hacettepe experience and review of literature","volume":"8","author":"Desteli","year":"2010","journal-title":"World J Surg Oncol"},{"key":"ref5371","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br J Cancer"},{"key":"ref3691","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2019.05.029","article-title":"Conservative surgery in stage I adult type granulosa cells tumors of the ovary: results from the MITO-9 study","volume":"154","author":"Bergamini","year":"2019","journal-title":"Gynecol Oncol"},{"key":"ref2951","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.1471-0528.2008.01775.x","article-title":"Should adnexal mass size influence surgical approach? A series of 186 laparoscopically managed large adnexal masses","volume":"115","author":"Ghezzi","year":"2008","journal-title":"BJOG"},{"key":"ref3441","first-page":"400","article-title":"Fertility preservation in women","volume":"378","author":"Donnez","year":"2018","journal-title":"N Engl J Med"},{"key":"ref3971","first-page":"928","article-title":"Cytoreductive surgery for advanced ovarian cancer: quo vadis?","volume":"25","author":"Schorge","year":"2011","journal-title":"Oncology (Williston Park)"},{"key":"ref4111","first-page":"3020","article-title":"[Prognostic significance of systematic retroperitoneal lymphadenectomy in patients with epithelial ovarian cancer: a Meta-analysis]","volume":"96","author":"Gu","year":"2016","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"312982","DOI":"10.1155\/2013\/312982","article-title":"Minimally invasive surgery in gynecologic oncology","volume":"2013","author":"Mori","year":"2013","journal-title":"ISRN Obstet Gynecol"},{"key":"ref2901","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.ajog.2004.11.018","article-title":"The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers","volume":"192","author":"Chi","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref3911","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/ijgc-2019-001116","article-title":"Role of staging surgery and adjuvant chemotherapy in adult patients with apparent stage I pure immature ovarian teratoma after fertility-sparing surgery","volume":"30","author":"Wang","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"ref1181","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1245\/s10434-016-5234-z","article-title":"Significance of the complete surgical staging of stage I malignant ovarian germ cell tumors","volume":"23","author":"Park","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"ref4891","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1023\/A:1008256431090","article-title":"A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study","volume":"8","author":"Lambert","year":"1997","journal-title":"Ann Oncol"},{"key":"ref4451","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/cncr.32620","article-title":"Fertility-sparing surgery and survival among reproductive-age women with epithelial ovarian cancer in 2 cancer registries","volume":"126","author":"Crafton","year":"2020","journal-title":"Cancer"},{"key":"ref2061","first-page":"144","article-title":"Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer","volume":"13","author":"Piccart","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"ref3201","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1525-1438.2006.00303.x","article-title":"Impact of initial surgical access on staging and survival of patients with stage I ovarian cancer","volume":"16","author":"L\u00e9curu","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"ref3991","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"key":"ref5131","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology\/Gynecologic Oncology Group study","volume":"37","author":"Walker","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref5271","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref3101","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jmig.2017.02.013","article-title":"Minimally invasive surgical staging in early-stage ovarian carcinoma: a systematic review and meta-analysis","volume":"24","author":"Bogani","year":"2017","journal-title":"J Minim Invasive Gynecol"},{"key":"ref1941","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/jnci\/djq362","article-title":"Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel","volume":"102","author":"Hoskins","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"ref4591","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/annonc\/mdi223","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study","volume":"16","author":"Aravantinos","year":"2005","journal-title":"Ann Oncol"},{"key":"ref3071","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jmig.2016.01.029","article-title":"Laparoscopic management of ovarian cancer patients with localized carcinomatosis and lymph node metastases: results of a retrospective multi-institutional series","volume":"23","author":"Gallotta","year":"2016","journal-title":"J Minim Invasive Gynecol"},{"key":"ref4101","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.3802\/jgo.2020.31.e67","article-title":"Lymphadenectomy for primary ovarian cancer: a systematic review and meta-analysis","volume":"31","author":"Chiyoda","year":"2020","journal-title":"J Gynecol Oncol"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"462.e1","DOI":"10.1016\/j.ajog.2013.07.016","article-title":"A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer","volume":"209","author":"Fagotti","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"ref3221","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s00464-013-3390-9","article-title":"Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience","volume":"28","author":"Gallotta","year":"2014","journal-title":"Surg Endosc"},{"key":"ref1741","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/jnci\/djj019","article-title":"Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients","volume":"98","author":"Earle","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"ref4001","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.AOG.0000192407.04428.bb","article-title":"Aggressive surgical effort and improved survival in advanced-stage ovarian cancer","volume":"107","author":"Aletti","year":"2006","journal-title":"Obstet Gynecol"},{"key":"ref3581","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/IGC.0b013e3182129842","article-title":"Fertility-sparing surgery for borderline ovarian tumors: oncologic safety and reproductive outcomes","volume":"21","author":"Song","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ygyno.2006.08.032","article-title":"Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women","volume":"104","author":"Zhang","year":"2007","journal-title":"Gynecol Oncol"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/IGC.0b013e3182129842","article-title":"Fertility-sparing surgery for borderline ovarian tumors: oncologic safety and reproductive outcomes","volume":"21","author":"Song","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"ref4721","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1200\/JCO.1992.10.5.718","article-title":"Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group","volume":"10","author":"Swenerton","year":"1992","journal-title":"J Clin Oncol"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol Oncol"},{"key":"ref4341","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jnci\/95.2.113","article-title":"International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma","volume":"95","author":"Trimbos","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"ref4421","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"100071","DOI":"10.1016\/j.eurox.2019.100071","article-title":"Fertility-Sparing surgery for young women with ovarian endometrioid carcinoma: a multicenteric comparative study using inverse probability of treatment weighting","volume":"4","author":"Kajiyama","year":"2019","journal-title":"Eur J Obstet Gynecol Reprod Biol X"},{"key":"ref1331","first-page":"67","article-title":"Current management of menopausal symptoms in cancer patients","volume":"16","author":"Barton","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2019.05.029","article-title":"Conservative surgery in stage I adult type granulosa cells tumors of the ovary: results from the MITO-9 study","volume":"154","author":"Bergamini","year":"2019","journal-title":"Gynecol Oncol"},{"key":"ref521","first-page":"103","article-title":"[Clinical comparative analysis of comprehensive laparoscopic and laparotomic staging of early-stage epithelial ovarian cancer]","volume":"52","author":"Xiong","year":"2017","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"ref1281","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.AOG.0000192407.04428.bb","article-title":"Aggressive surgical effort and improved survival in advanced-stage ovarian cancer","volume":"107","author":"Aletti","year":"2006","journal-title":"Obstet Gynecol"},{"key":"ref4031","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.2015.60.9719","article-title":"Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial","volume":"33","author":"Eeles","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref5201","first-page":"2803","article-title":"Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer","volume":"29","author":"Zeimet","year":"2009","journal-title":"Anticancer Res"},{"key":"ref2111","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1200\/JCO.2015.66.2346","article-title":"Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group Clinical Trials","volume":"34","author":"Hershman","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.hoc.2011.10.004","article-title":"Current surgical management of ovarian cancer","volume":"26","author":"Schorge","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref1351","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1013::AID-CNCR17>3.0.CO;2-1","article-title":"Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial","volume":"86","author":"Guidozzi","year":"1999","journal-title":"Cancer"},{"key":"ref2231","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.5517","article-title":"Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology\/Gynecologic Oncology Group (GOG) study [abstract]","volume":"36","author":"Burger","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref4441","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1470-2045(20)30218-7","article-title":"Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial","volume":"21","author":"Blagden","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref1601","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/02841860151116420","article-title":"A systematic overview of chemotherapy effects in ovarian cancer","volume":"40","author":"H\u00f6gberg","year":"2001","journal-title":"Acta Oncol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ygyno.2005.07.008","article-title":"Who should operate on patients with ovarian cancer? An evidence-based review","volume":"99","author":"Giede","year":"2005","journal-title":"Gynecol Oncol"},{"key":"ref2131","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/annonc\/mds494","article-title":"A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG","volume":"24","author":"Banerjee","year":"2013","journal-title":"Ann Oncol"},{"key":"ref4571","first-page":"3646","article-title":"Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial","volume":"15","author":"Li","year":"2018","journal-title":"Oncol Lett"},{"key":"ref1581","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199004123221501","article-title":"Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials","volume":"322","author":"Young","year":"1990","journal-title":"N Engl J Med"},{"key":"ref5041","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1006\/gyno.1994.1220","article-title":"A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer","volume":"54","author":"Kirmani","year":"1994","journal-title":"Gynecol Oncol"},{"key":"ref2421","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-8258(03)00377-9","article-title":"First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up","volume":"90","author":"Fujiwara","year":"2003","journal-title":"Gynecol Oncol"},{"key":"ref2511","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"ref3451","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO clinical practice guideline update","volume":"36","author":"Oktay","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref4971","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG Oncology\/Gynecologic Oncology Group study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin Cancer Res"},{"key":"ref3471","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12885-020-06828-y","article-title":"Fertility sparing surgery vs radical surgery for epithelial ovarian cancer: a meta-analysis of overall survival and disease-free survival","volume":"20","author":"Liu","year":"2020","journal-title":"BMC Cancer"},{"key":"ref2091","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00001813-199903000-00001","article-title":"Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg","volume":"10","author":"Wils","year":"1999","journal-title":"Anticancer Drugs"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13048-018-0423-y","article-title":"Age-dependent difference in impact of fertility preserving surgery on disease-specific survival in women with stage I borderline ovarian tumors","volume":"11","author":"Sun","year":"2018","journal-title":"J Ovarian Res"},{"key":"ref5421","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref1851","first-page":"3646","article-title":"Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial","volume":"15","author":"Li","year":"2018","journal-title":"Oncol Lett"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"341","DOI":"10.23736\/S0026-4806.19.06132-9","article-title":"Laparoscopy vs. laparotomy for advanced ovarian cancer: a systematic review of the literature","volume":"110","author":"Gueli Alletti","year":"2019","journal-title":"Minerva Med"},{"key":"ref2031","first-page":"57","article-title":"Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study","volume":"24","author":"Skarlos","year":"1997","journal-title":"Semin Oncol"},{"key":"ref3151","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1007\/s00464-017-5899-9","article-title":"Laparoscopy for primary cytoreduction with multivisceral resections in advanced ovarian cancer: prospective validation. \u201cThe times they are a-changin\u201d?","volume":"32","author":"Ceccaroni","year":"2018","journal-title":"Surg Endosc"},{"key":"ref4781","first-page":"144","article-title":"Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer","volume":"13","author":"Piccart","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"ref2801","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.2016.70.1474","article-title":"Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Ferrell","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref4631","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2018.07.021","article-title":"Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology\/Gynecologic Oncology Group study","volume":"151","author":"Olawaiye","year":"2018","journal-title":"Gynecol Oncol"},{"key":"ref3261","doi-asserted-by":"crossref","first-page":"312982","DOI":"10.1155\/2013\/312982","article-title":"Minimally invasive surgery in gynecologic oncology","volume":"2013","author":"Mori","year":"2013","journal-title":"ISRN Obstet Gynecol"},{"key":"ref3661","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ygyno.2017.08.013","article-title":"Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base","volume":"147","author":"Nasioudis","year":"2017","journal-title":"Gynecol Oncol"},{"key":"ref2021","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/gyno.1997.4690","article-title":"Randomized study comparing carboplatin\/cyclophosphamide and cisplatin\/cyclophosphamide as first-line treatment in patients with stage III\/IV epithelial ovarian cancer and small volume disease","volume":"66","author":"Meerpohl","year":"1997","journal-title":"Gynecol Oncol"},{"key":"ref5391","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","article-title":"Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation","volume":"72","author":"Popova","year":"2012","journal-title":"Cancer Res"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","article-title":"Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome","volume":"59","author":"Fagotti","year":"2016","journal-title":"Eur J Cancer"},{"key":"ref3751","first-page":"898","article-title":"[Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery]","volume":"47","author":"Yang","year":"2012","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"ref5281","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"ref1701","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2407-12-31","article-title":"Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study","volume":"12","author":"Rutten","year":"2012","journal-title":"BMC Cancer"},{"key":"ref2931","first-page":"CD005344","article-title":"Laparoscopy versus laparotomy for FIGO Stage I ovarian cancer","author":"Medeiros","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"ref1811","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref4921","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref3461","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00404-017-4594-3","article-title":"Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation","volume":"297","author":"Sch\u00fcring","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"ref2341","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2014.10.023","article-title":"Ovarian cancer in the United States: contemporary patterns of care associated with improved survival","volume":"136","author":"Cliby","year":"2015","journal-title":"Gynecol Oncol"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1245\/s10434-014-3783-6","article-title":"Influence of intraperitoneal dissemination assessed by laparoscopy on prognosis of advanced ovarian cancer: an exploratory analysis of a single-institution experience","volume":"21","author":"Vizzielli","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"ref4551","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2005.02.4067","article-title":"Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin\/paclitaxel versus carboplatin\/paclitaxel","volume":"24","author":"Greimel","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref2991","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ajog.2013.04.013","article-title":"Staging laparoscopy for the management of early-stage ovarian cancer: a metaanalysis","volume":"209","author":"Park","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"ref4911","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"ref5311","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br J Cancer"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1007\/s00464-017-5899-9","article-title":"Laparoscopy for primary cytoreduction with multivisceral resections in advanced ovarian cancer: prospective validation. \u201cThe times they are a-changin\u201d?","volume":"32","author":"Ceccaroni","year":"2018","journal-title":"Surg Endosc"},{"key":"ref4481","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N Engl J Med"},{"key":"ref4151","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/IGC.0000000000000787","article-title":"Incidence of lymph node metastases in apparent early-stage low-grade epithelial ovarian cancer: a comprehensive review","volume":"26","author":"Lago","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"ref5261","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"ref3131","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jmig.2016.09.018","article-title":"Minimally invasive surgical staging for ovarian carcinoma: a propensity-matched comparison with traditional open surgery","volume":"24","author":"Ditto","year":"2017","journal-title":"J Minim Invasive Gynecol"},{"key":"ref2981","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ejso.2013.05.007","article-title":"Laparoscopic staging for apparent early stage ovarian or fallopian tube cancer. First case series from a UK cancer centre and systematic literature review","volume":"39","author":"Brockbank","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"ref4751","first-page":"57","article-title":"Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study","volume":"24","author":"Skarlos","year":"1997","journal-title":"Semin Oncol"},{"key":"ref1621","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jnci\/95.2.113","article-title":"International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma","volume":"95","author":"Trimbos","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"ref1671","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"ref1921","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1016\/j.ejca.2010.06.124","article-title":"Paclitaxel\/carboplatin versus topotecan\/paclitaxel\/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study","volume":"46","author":"Bolis","year":"2010","journal-title":"Eur J Cancer"},{"key":"ref2781","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1016\/j.ejca.2013.06.013","article-title":"Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial","volume":"49","author":"van Meurs","year":"2013","journal-title":"Eur J Cancer"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00404-019-05160-6","article-title":"Prognostic factors and oncological outcomes of ovarian yolk sac tumors: a retrospective multicentric analysis of 99 cases","volume":"300","author":"Boyraz","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"ref3561","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/cncr.32620","article-title":"Fertility-sparing surgery and survival among reproductive-age women with epithelial ovarian cancer in 2 cancer registries","volume":"126","author":"Crafton","year":"2020","journal-title":"Cancer"},{"key":"ref3181","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11701-018-0838-x","article-title":"Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis","volume":"13","author":"Cardenas-Goicoechea","year":"2019","journal-title":"J Robot Surg"},{"key":"ref1381","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.3802\/jgo.2020.31.e67","article-title":"Lymphadenectomy for primary ovarian cancer: a systematic review and meta-analysis","volume":"31","author":"Chiyoda","year":"2020","journal-title":"J Gynecol Oncol"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00404-017-4594-3","article-title":"Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation","volume":"297","author":"Sch\u00fcring","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"ref4851","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/annonc\/mds494","article-title":"A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG","volume":"24","author":"Banerjee","year":"2013","journal-title":"Ann Oncol"},{"key":"ref3631","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/bjc.2013.241","article-title":"Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary","volume":"109","author":"Mangili","year":"2013","journal-title":"Br J Cancer"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/AOG.0000000000002796","article-title":"Laparoscopic surgical algorithm to triage the timing of tumor reductive surgery in advanced ovarian cancer","volume":"132","author":"Fleming","year":"2018","journal-title":"Obstet Gynecol"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/19\/2\/article-p191.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/19\/2\/article-p191.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T14:37:47Z","timestamp":1697812667000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/19\/2\/article-p191.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":512,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2021.0007","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}